Profile
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company’s most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. Edesa is also planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Event details
Event contact
Participants
-
Basetwo is a low-code platform that enables scientists and engineers to easily build digital twins of their lab, pilot… -
BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring… -
Bright Angel Therapeutics (BAT) is a pre-clinical stage biotechnology company focused on the development… -
Canurta is revolutionizing healthcare by developing innovative botanical therapeutics using rare cannflavins for… -
Mississauga's life sciences sector is a thriving hub of innovation and growth. With a highly skilled workforce and… -
Custom Biologics provides regulatory compliant biological testing and assay services for all phases of biotherapeutic… -
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and… -
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative… -
Medexus Pharmaceuticals Inc. is a leading innovative and rare disease pharmaceutical company that has core capabilities… -
Nanovista is developing novel, multi-modality imaging agents for oncology. Nanovista is enabling surgical oncologists… -
Omnium Global is a Toronto-based scientific management consulting firm that has been delivering solutions to clients… -
Orion Biotechnology is a clinical stage company founded in 2017, with established R&D operations in Geneva,… -
Pluristyx, powered by panCELLa, is an advanced therapy tools and services company whose primary mission is to help… -
PolyAnalytik Inc. (PAI) was founded in 2007 and incorporated in May 2008 with its headquarters… -
ProteinQure is the best computational platform for peptide drug discovery. ProteinQure partners with pharma to deliver… -
Q&C Services wrote the book on regulatory compliance. Over 150,000 copies of its authoritative, pocket sized Blue… -
QurCan Therapeutics is a biotech company that utilizes next-generation tissue-selective, blood-brain barrier-… -
Spiderwort is a biotechnology company with a transformative platform of cellulose-based biomaterials that will serve as… -
Sterimax Inc is the largest privately owned provider of sterile injectables in Canada. Sterimax is a fast growing… -
TREVENTIS™ Corporation is dedicated to treating and preventing protein misfolding diseases. its innovative… -
Virica is a viral vector enhancer company. Virica pioneered a new enhancer category called Viral Sensitizers (…